Introduction
The luteinizing hormone releasing hormone (LHRH) functions in the mechanisms of evolution and conception. Over a thousand analogs of LHRH have apparently been synthesized, some of which were significant agonists, super-agonists or antagonists.
We have synthesized and bioassayed a series of analogs (Table I) , most of which have the azaglycineamide (Azagly) moiety, I, in position 10. For three of these analogs, the corresponding peptides having the glycinamide (Gly) moiety, II, in position 10 were synthesized for comparison of inhibitory activities.
I, -NH-NH-CO-NHo II, -NH-CH2-CO-NH2
The rationale for synthesizing and bioassaying these analogs with Azagly was that the C-terminal might be protected, in vivo, against enzymic degradation in contrast to the corresponding Gly 10 analogs. Such protection might not be observed by routine in vivo assays for activity, but might be Variations of the solid phase method of Merrifield were used to synthesize the peptides. The glycinamide analogs (compounds 3,7, and 9) were prepared from benzhydrylamine resins. The azaglvcinamide analogs (compounds 1, 2, 4, 5, 6, 8 and 10) were prepared from chloromethyl Merrifield resins by attaching the penultimate amino acid (Pro) to the resin and completing of the synthesis to the Nterminus. The C-terminal Azagly moiety was then introduced after the peptide was cleaved from the resin.
Two methods for introducing the Azagly residue were studied. Analogs 4. 6, 8, and 10 were synthesized by cleaving the peptide-Merrifield resin with hydrogen fluoride to give the unprotected Nacetylated peptide carboxylic acids. Condensation of the latter with semicarbazide (azaglvcinamide) by means of N-N'-dicyclohexylcarbodiimide (DCC) afforded the peptides for purification.
Analogs 1,2, and 5 were synthesized by a variation of the azide procedure of Dutta et al. [1] which gave better yields and fewer difficulties with purification than the method which coupled semicarbazide by DCC. In this azide procedure, the peptide-Merrifield resins were subjected to hydrazinolysis to afford protected peptides as hydrazides. Treatment of these hydrazides with butyl nitrite in acidic dioxan gave azides which were then allowed to react with semicarbazide. The protecting groups were then removed with liquid HF. The conditions of hydrazinolysis may have possibly resulted in minor loss of the N-terminal acetyl group. Phillips [2] , and Schmer and Kreil [3] . have shown that complete removal of N-acetyl groups by hydrazinolysis is possible at 100 °C for about 17 h. Ail of the Azaglycontaining peptides gave strong positive tests [4] for hydrazine following complete acid hydrolysis.
A new method of introducing the azaglycine moiety was extended. Dutta and Morlev [5] reported the use of cyanate ion to convert hydrazides to azaamino acid derivatives. In this method, a peptide hydrazide Avas treated Avith cyanate ion in acidic solution. We used X-Z-L-proline (11) [7] indicated an incomplete acylation of amino groups, a second coupling was performed by a repetition of steps 6 through 14. Sequences resulting from incomplete coupling, even after double coupling Avere terminated by acetylation. Acetylation of the N-terminal amino acid moiety Avas accomplished by adding 25% acetic anhydride in CHoCL-pyridine in place of steps 10 and 11 of the coupling program. Peptides Avere removed from BHA resins by treatment with anhydrous liquid HF containing ca. 20% anisole for l'h at 0 °C. as described [8] , TLC was performed on E. Merck silica gel G plates Avith detection by fluorescence, chlorine-tolidine spray, and ferric ferricyanide. Values for Rf 1 , Rf 2 , Rf 3 and A'/ 4 refer to the systems: 1-butanol-acetic acid-ethyl acetate-Avater (1:1:3:1), ethanol-Avater Biological assays for in vitro LH releasing and in vivo antiovulatory activity were carried out. as described [9] 
Protected peptide hydrazides
To about 1 g of the protected peptide-Merrifield resin suspended in DMF, was added 0.77 ml of anhydrous hydrazine, and the mixture stirred 4 d at room temperature. The cleaved resin was filtered and washed with DMF. The combined filtrate and washings were evaporated, in vacuo (oil pump), and the residue was dried overnight over concd. H2SO4. After an ether wash, the residue was dissolved in an appropriate solvent. The following hydrazides were obtained by using the indicated dissolution and precipitation solvents [11, 12] ,
Pro-NHNH-CO-NH2:
The general procedure of Klausner and Bodanszky [13] was followed. To a solution of 0.467 g (0.266 mM) of hydrazide 14 in 2.5 ml of DMF at -30 °C, was added 0.22 ml (1.33 mM) of 6 M HCl in dry dioxan, followed by 0.08 ml of 50% isoamyl nitrite in isoamvl alcohol (0.298 mM, 12% excess). After 30 min at -25 to -30 °C, the solution was cooled to -60 °C. Triethylamine (0.185 ml, 1.33 mM) was added, followed by semicarbazide hydrochloride (35.6 mg. 0.319 mM, 20% excess), and additional triethylamine (0.044ml, 0.319 mM). The suspension was stirred at 4 °C for 24 h then at room temperature for two days. A further 35.6 mg-portion of semicarbazide and 0.044 ml of triethylamine were added, and the mixture was stirred for three days. The product was precipitated with water and filtered. The same procedure was used for all three hydrazides.
N-Z-L-Prolylhydrazide p-toluenesulfonate 12:
To 598 mg (2 mM) of N-Z-L-proline and 280 mg (2mM) of 1-HBT in 6 ml of CH2C12, was added 458 mg (2.4 mM) of DCC. The mixture was swirled for ca. 5 min at room temperature, and filtered into a solution of 1.30 g (39.2 mM) of anhydrous N2H4 in 8 ml of CH3CN with vigorous magnetic stirring. After 5 min. the mixture was evaporated to a small volume on a rotating evaporator. To remove residual N2H4, 3 ml of 1-butanol was added and evaporated, and this step was repeated. Ethyl acetate (5 ml) was added, and some insoluble material was removed by filtration. The filtrate was treated with 380 mg of ^-toluenesulfonic acid monohydrate which resulted in a clear solution, from which a crystalline solid rapidly separated. 
Results and Discussion
Dutta et al. [1] reported the synthesis of some analogs of LHRH which have Azagly 10 moieties.
They found that some of their analogs had agonist and others had antagonist activities, in certain assays. Simpson et al. [14] found [D-Xal(2) 6 , Azagly 10 ]-LHRH (Nal(2) is 3(2-naphthalene)-alanine) to be one of the most potent known agonists. Since the Azagly residue in position 10 of antagonists might protect the C-terminal from enzymatic degradation, in vivo, in contrast to enzymic attack of the naturally occurring Gly 10 in LHRH, it was considered important to extend the chemical and biological data on Azagly 10 analogs of LHRH, and particularly for analogs which have multiple substitutions for the amino acids in LHRH. These substitutions have been based upon the results of investigations by several groups of investigators, including Ling and Vale [15] ; Prasad et al. [16] ; Coy et al. [17] ; Rivier et al. [18] ; Channabasavaiah and Stewart [19] .
Our synthesis of seven new Azagly 10 analogs resulted from our use and comparison of three procedures to introduce the Azagly 10 moiety. The newest procedure involved the use of cyanate ion in an acidic medium to convert hydrazides into Azagly moieties, and appeared to provide a simpler and better procedure. For a preliminary model, this method was used to synthesize Z-L-prolylazaglycinamide (13); the analytical data and melting point of 13 were in agreement, but the optical rotation was considerably higher than that in data reported by Dutta et al. [1] .
The general experience of investigators, who have synthesized analogs of LHRH toward more effective and potent inhibitors of the release of LH for the control of ovulation, has been that relationships between sequence and anti-ovulatory activity may have some generally, but the generality may be limited. The relationships may be applicable to restricted groups of sequence changes. On the basis of such generality and limitation, the following interpretations can be made of the antiovulatory activities of the ten new analogs according to the in vivo data of Table III a This product behaved as a mixture of two peptides, which were difficult to separate. The limitation of sample and lack of feasibility to resynthesize this peptide justified assay of the sample. This sample may have contained a little of the deacetylated peptide; b Purification of this analog was difficult. Eventually, a preparation was obtained which showed two approximately equal peaks by HPLC and two spots by TLC; R[ values of 0.73 and 0.92. The spot having Itf 3 0.73 was ninhydrin positive, but the spot of i?f 3 0.02 was ninhydrin negative. Since the analysis for amino acids was satisfactory, it was concluded that the peptide with R( 0.73 may be deacetylated and the peptide with Rf 0.02 is the N-Ac-D-Ala 1 -peptide; c Qualitative tests for hydrazine in the hydrolysate were positive. Tryptophan was generally detected, but not quantitated. Parachlorophenylalanine was detected, but not quantitated. Parachlorophenylalanine and tryptophan were quantitated as a pair using a separate standard containing these two amino acids. The data on the in vitro assay of these analogs for antagonist activity are in Table IV . All of the analogs except 5 were assayed as described by Bowers et al. [20] , which was based upon using pituitaries from 20-dav old female rats of the CD1 strain. The analog and LHRH were added at appropriate periods of incubation, and the release of LH and FSH were recorded as A LH and A FSH. The LH and FSH values are in nanograms, based on standards. Analog 5 was assayed in vitro, by the As a group, these nine analogs were more inhibitory for the release of LH than for FSH, since analogs 1, 2, 3, and 7 did not inhibit release of FSH at levels effective for inhibition of the release of LH, but analogs 4, 6. 8, 9, and 10 did inhibit release of FSH at the same level which inhibited LH. By the culture of dispersed pituitary cells, analog 5, at a level of 0.02 nanograms, significantly (p <0.001) inhibited the release of LH.
It is evident that the Azagly 10 moiety in comparison with the Gly 10 moiety in analogs which are otherwise identical does not cause a significant reduction in activity for inhibition of ovulation. The Azagly 10 analogs are apparently equal to the Gly 10 analogs in activity, and perhaps may be desirable to study the metabolic stability of Azagly 10 analogs under conditions which more closely simulate potential clinical use.
